Adjuvant and neoadjuvant applications of BRAF and MEK inhibitors showed exciting results, opening new treatment avenues, particularly for recurrent tumours and for patients who are poor surgical and radiotherapy candidates, offering them an opportunity to reduce treatment related morbidity. The gene discussed is MAP2K7; the disease is neoplasm.